Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02131584 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia

StatusActive, Not Recruiting
PhasePhase 2
Started2014-09-02
View on ClinicalTrials.gov ↗
This phase II trial studies how well ruxolitinib phosphate works in reducing fatigue in patients with chronic lymphocytic leukemia. Ruxolitinib phosphate may stop the growth of cancer cells by blocking a protein called Janus kinase (JAK) that is needed for cell growth and may also help control fatigue, decrease the size of lymph nodes and/or lower the number of chronic lymphocytic leukemia cells in the blood.

Amendment history 2 changes detected by DataLookout

2026-09-04
Primary completion pushed: 2026-09-30 → 2028-09-30
2026-09-04
Completion pushed: 2026-09-30 → 2028-09-30
Trial Details
NCT Number NCT02131584
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions Chronic Lymphocytic Leukemia
Enrollment 10 participants
Start Date 2014-09-02
Primary Completion 2028-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-03